Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 6 to 7 amino acid residues in defined sequence
Reexamination Certificate
2002-06-04
2008-10-28
Tsang, Cecilia (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
6 to 7 amino acid residues in defined sequence
C530S328000, C514S002600
Reexamination Certificate
active
07442763
ABSTRACT:
The present invention relates to a composition of matter comprising novel prostaglandin E2 receptor antagonists, and their use in treatments for regulating the fluid filtration in the kidney, preventing bone mineral loss in osteoporosis and dental disease and additionally, closure of ductus arteriosus (DA) in premature infants or fetal animals. Additionally, the compositions include linear peptides, peptide analogs, and peptidomimetics.
REFERENCES:
patent: 5508384 (1996-04-01), Murphy et al.
patent: 5605814 (1997-02-01), Abramovitz et al.
patent: 5759789 (1998-06-01), Abramovitz et al.
patent: 5955575 (1999-09-01), Peri et al.
patent: 6300312 (2001-10-01), Chemtob et al.
patent: 6984719 (2006-01-01), Chemtob et al.
patent: 2003/0017988 (2003-01-01), Peri et al.
patent: 2004/0235749 (2004-11-01), Chemtob et al.
patent: WO 92/04450 (1992-03-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/00551 (1995-01-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/29193 (1995-11-01), None
patent: WO 96/06856 (1996-03-01), None
patent: WO 96/19233 (1996-06-01), None
patent: WO 96/23225 (1996-08-01), None
patent: WO 97/12624 (1997-04-01), None
patent: WO 97/18236 (1997-05-01), None
patent: WO 97/34621 (1997-09-01), None
patent: WO 98/10651 (1998-03-01), None
patent: WO 98/26070 (1998-06-01), None
patent: WO 99/55849 (1999-11-01), None
Schramm et al. “The Inhibition of Human Immunodeficiency Virus Proteases By Interface Peptides”, 1996, Antiviral Research, vol. 30. pp. 155-170.
Schramm, H.J., The inhibition of human immunodeficiency virus proteases by ‘interface peptides’, Antiviral Research, 1996, vol. 30 No. 2,3:155-70.
Ichikawa, A., etal., Molecular aspects of the structures and functions of the prostaglandin E receptors, 1996, J. Lipid Mediators Cell Signalling: 14: 83-87.
Bastien, Y.,etal., Cloning, Functional Expression, and Characterization of the Human Prostaglandin E2Subtype*, 1994, J. Biol.Chem. 269 (16): 11873-77.
Bhattacharya, M.,etal., Developmental Changes in Prostaglandin E2Receptor Subtypes in Porcine Ductus Arteriosus, 1999, Circulation. 100: 1751-56.
Nguyen,M., etal.,The prostaglandin receptor EP4triggers remodelling of the cardiovascular system at birth, 1997, Nature. 390: 78-81.
Segi, E., etal.,Patent Ductus Arteriosus and Neonatal Death in Prostaglandin Receptor EP4-Deficient Mice, 1998,Biochemical and Biophysical Research Comm. 246: 7-12.
Breyer, M.D., etal., Regulation of renal function by prostaglandin E receptors, 1998, Kidney Int. 54 (Supple.67): S88-94.
Morath, R.,etal. Immunolocalization of the Four Prostaglandin E2Receptor Proteins EP1, EP2, EP3, and EP4 in Human Kidney, 1999, J.Am.Soc.Nephrol. 10: 1851-60.
Breyer, M.D., etal., Differential localization of prostaglandin E receptor subtypes in human kidney, 1998, Am.J.Physiol. 270: F912-918.
Scholondoff, D. etal.,Prostaglandins and other arachidonic acid metabolites in the kidney, 1986, Kidney Int. 29: 108-19.
Friedlander,G., etal., PGE2Binding Sites and PG-Stimulated Cyclic AMP Accumulation in Rat Isolated Glomeruli and Glomerular Cultured Cells, 1983, Mol. Cell. Endocrinol. 30: 201-214.
Sugimoto, Y.,etal., Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in Kidney, 1994, American Physiological Society, F823-G828.
Tai, H.,etal., Transcriptional Induction of Cyclooxygenase-2 in Osteoblasts Is Involved in Interleukin-6-Induced Osteoclast Formation*, 1997, Endocrinology, 138: 2372-2379.
Narumiya, S, etal., Prostanoid Receptors: Structures, Properties, and Functions, 1999, Physiol. Rev. 79: 1193-1226.
Merrifield, R.B., Solid Phase Peptide Synthesis, Stewart & Young, W h Freeman Co., San Francisco, 1969, 2149-2154.
Arban, D., etal., Regulation of prostanoid vasomotor effects and receptors in choroidal vessels of newborn pigs, 1997, Am.J. Physiol. 272: R995-1001.
Teyssier, G., etal., Real-Time Cross-Sectional Ultrasonographic Imaging of the Newborn Lamb Heart. Technical Aspects, 1989, J. Cardiovascular Technol. 8: 259-266.
Rudinger, J., Characteristics of the amino acids as components of a peptide hormone sequence. In Peptide Hormones, Ed. By JA Parsons. University Park Press, pp. 1-7, 1976,
Lofts, F.J., etal., Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro in vivo, Oncogene 8: 2813-2820, 1993.
Wise, H., etal, Activation of the Prostaglandin EP4-Receptor Subtype is Highly Coupled to Inhibition of N-Formyl-Methionyl-Leucyl-Phenylalanine Stimulated Rat Neutrophil Aggregation Prostaglandins, Leukotriens and Essential Fatty Acids, Vo. 58, 1998, pp. 77-84.
Abramovitz, M., etal., Cloning and Expression of a cDNA for the Human Prostanoid FP Receptor, 1994, Journal of Biol. Chem., vol. 269, No. 4, pp. 2632-2636.
Coleman, RA.,etal., VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes, 1994, Pharmacological Reviews, vol. 46, No. 2, pp. 205-229.
Crankshaw DJ., etal., Effects of some naturally occurring prostanoids and some cycloxygenase inhibitors on the contractility of the human lower uterine segment in vitro1, 1994, Can J Physiol Pharmacol 72: pp. 870-874.
Griffin, BW., etal., AL-8810: A Novel Prostaglandin F2aAnalog with Selective Antagonist Effects at the Prostaglandin F2a(FP) Receptor, 1999, Journal of Pharmacology and Experimental Therapeutics, vol. 290, No. 3, pp. 1278-1284.
Li, D. etal., Inhibition of Prostaglandin Synthesis in Newvorn Pigs Increases Cerebral Microvessel Prostaglandin F2aand Prostaglandin E2Receptors, Their Second Messengers and Vasoconstrictor Response to Adult Levels, 1996, The Journal of Pharmacology and Experimental Therapeutics, vol. 278, No. 1, pp. 370-377.
Li, D. etal., Key role for cyclooxygenase-2 in PGE2and PGF2areceptor regulation and cerebral blood flow of the newborn, 1997, The American Physiological Society, pp. R1283-R1290.
Lumsden, MA., etal., Is Prostaglandin F2Involved In The Increased Myometrial Contractility Of Primary Dysmenorrhoea?, 1983, Prostaglandins 25(5); pp. 683-692.
Novy, MJ., etal., Role of Prostaglandins, Prostacyclin, and Thromboxanes in the Physiologic Control of the uterus and in Parturition, 1980, Seminars in Perinatology 4: pp. 45-66.
Powell, AM., etal., Menstrual-PGF2aAnd TXA2In Normal and Dysemnorrheic Women and Their Temporal Relationship to Dysemenorrhea1, 1985, Prostaglandins vol. 29, No. 2., pp. 273-289.
Strader CD., etal., Structure and Function of G Protein-Coupled Receptors, 1994, Annu. Rev. Biochem. 63: pp. 101-132.
Taylor,JM, etal., Peptides As Probes For G Protein Signal Transduction, 1994, Cell Signal 6: pp. 841-849.
Chemtob Sylvain
Peri Krishna G.
Audet Maury
Hopital Sainte-Justine
Klauber & Jackson
Tsang Cecilia
LandOfFree
Compositions for treating abnormalities in glomerular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treating abnormalities in glomerular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treating abnormalities in glomerular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3989508